Moderna and Merck announced that their AI-built cancer vaccine, intismeran autogene, achieved positive Phase 3 results in melanoma patients, marking the first success for a personalized cancer therapy. The vaccine uses AI to analyze each patient's tumor mutations and create a unique treatment, a breakthrough in precision medicine. The main challenge now is scaling production to deliver personalized doses within 4-8 weeks, a complex manufacturing and logistical task. Moderna is expanding trials to other cancers and exploring the platform for other diseases, but economic viability at scale remains to be proven.
Merck's market cap stands at $355.10 billion with a dividend yield of 2.36%, while Moderna's market cap is $57.48 billion as of September 15, 2026, 03:21 WIB. Moderna's stock price is up 1.61% to USD 146.29, and Merck's price increased 0.55% to USD 144.72 on Pluang. These figures highlight the significant scale and investor interest in both companies involved in the breakthrough AI-built cancer vaccine development.
Moderna and Merck released Phase 3 trial results showing their personalized mRNA cancer vaccine, combined with Keytruda, reduces melanoma recurrence or death risk by 42% compared to Keytruda alone. Specialists see this as a significant breakthrough t...
Moderna's stock dropped 4% following an earlier 18% plunge after the release of positive late-stage results for its personalized melanoma vaccine co-developed with Merck. Although the vaccine showed a reduction in melanoma recurrence risk, the result...
Moderna's shares fell nearly 18% after positive Phase 3 results for its personalized melanoma vaccine with Merck were leaked early, causing market uncertainty despite the promising data. Meanwhile, SpaceX is negotiating with major infrastructure firm...
Moderna's stock dropped sharply by over 21% in two days following the leak of early Phase 3 trial results for its personalized cancer vaccine and a major downgrade from Citi, which issued a 'Sell' rating and an $80 price target. Despite the leaked re...
Moderna's stock fell up to 25% following the leak of partial data on its cancer vaccine developed with Merck, despite the full phase 3 trial results later showing positive outcomes. The vaccine, combined with Merck's Keytruda, reduced the risk of mel...
